ИСТОРИЯ РОЖДЕНИЯ СТАТИНОВ НОВЫЕ ПЕРСПЕКТИВЫ
https://doi.org/10.21518/2079-701X-2017-11-202-207
Аннотация
Статины используются со второй половины XX века. Прошло достаточно времени, чтобы понять истинное значение роли статинов в лечении сердечно-сосудистых заболеваний. Большой вклад в этом напправлении вносит новая область в изучении статинов – сердечная недостаточность с сохранной фракцией выброса.
Об авторах
З. В. ДрееваРоссия
Москва
Ф. Т. Агеев
Россия
Доктор медицинских наук, профессор.
Москва
Список литературы
1. Steinberg D. Chemotherapeutic approaches to the problem of hyperlipidemia. Adv Pharmacol, 1962, 1: 59-159.
2. Cottet J, Redel J, Krumm-Heller C, and Tricaud ME. Hypocholesterolemic property of sodium phenylethylacetate (22 TH) in the rat. Bull Acad Natl Med, 1953, 137: 441-442.
3. Cottet J, Mathivat A, and Redel J. Therapeutic study of a synthetic hypocholesterolemic agent: phenyl-ethyl-acetic acid. Presse Med, 1954, 62: 939-941.
4. Fredrickson DS and Steinberg D. Inhibitors of cholesterol biosynthesis and the problem of hypercholesterolemia. Ann N Y Acad Sci, 1956, 64: 579-589.
5. Steinberg D, Fredrickson DS and Avigan J. Effects of 4-cholestenone in animals and in man. Proc Soc Exp Biol Med, 1958, 97: 784-790.
6. Steinberg D and Fredrickson DS. Inhibition of lipid synthesis by alpha-phenyl-N-butyrate and related compounds. Proc Soc Exp Biol Med, 1955, 90: 232-236.
7. Fredrickson DS and Steinberg D. Failure of alpha-phenylbutyrate and beta-phenylvalerate in treatment of hypercholesterolemia. Circulation, 1957, 15: 391-396.
8. Oliver MF and Boyd GS. Effect of phenylethylacetic acid and its amide (hyposterol) on the circulating lipids and lipoproteins in man. Lancet, 1957, 273: 829-830.
9. Grande F, Anderson JT and Keys A. Phenyl butyramide and the serum cholesterol concentration in man. Metabolism, 1957, 6: 154-160.
10. Fredrickson DS, Peterson RE and Steinberg D. Inhibition of adrenocortical steroid secretion by delta 4-cholestenone. Science, 1958, 127: 704-705.
11. Tomkins GM, Nichols CW, Chapman DD et al. Use of delta 4-cholestenone to reduce the level of serum cholesterol in man. Science, 1957, 125: 936-937.
12. Blohm TR and MacKenzie RD. Specific inhibition of cholesterol biosynthesis by a synthetic compound (MER-29). Arch Biochem Biophys, 1959, 85: 245-249.
13. Avigan J, Steinberg D, Thompson MJ and Mosettig E. Mechanism of action of MER-29, an inhibitor of cholesterol biosynthesis. Biochem Biophys Res Commun, 1960, 2: 63-65.
14. Yamamoto A, Sudo H, and Endo A. Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis, 1980, 35: 259-266.
15. Mabuchi H, Haba T, Tatami R et al. Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. N Engl J Med, 1981, 305: 478-482.
16. Сергиенко И.В. История появления статинов. Атеросклероз и дислипидемии, 2011, 1. http://cyberleninka.ru/article/n/istoriya-poyavleniyastatinov.
Рецензия
Для цитирования:
Дреева ЗВ, Агеев ФТ. ИСТОРИЯ РОЖДЕНИЯ СТАТИНОВ НОВЫЕ ПЕРСПЕКТИВЫ. Медицинский Совет. 2017;(11):202-207. https://doi.org/10.21518/2079-701X-2017-11-202-207
For citation:
Dreeva ZV, Ageev FT. HISTORY OF STATINS DEVELOPMENT. NEW PROSPECTS. Meditsinskiy sovet = Medical Council. 2017;(11):202-207. (In Russ.) https://doi.org/10.21518/2079-701X-2017-11-202-207